Changes in saliva interleukin-6 levels in patients with oral squamous cell carcinoma

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 110, Issue 3, 2010, Pages 330-336

  Sato, Jun ^a   Goto, Jun ^a   Murata, Tsubasa ^a   Kitamori, Shogo ^a   Yamazaki, Yutaka ^a   Satoh, Akira ^a   Kitagawa, Yoshimasa ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78049371680     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2010.03.040     Document Type: Article

References (35)

1. Nagler R, Bahar G, Shpitzer T, Feinmesser R. Concomitant analysis of salivary tumor markers - a new diagnostic tool for oral cancer. Clin Cancer Res 2006;12:3979-84.
2. St. John MAR, Li Y, Zhou X, Denny P, Ho CM, Mintemagno C, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;103:929-35.
3. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 2008;14:6246-52.
4. Wang YF, Chang SY, Tai SK, Li WY, Wang LS. Clinical significance of interleukin-6 and interleukin-6 receptor expressions in oral squamous cell carcinoma. Head Neck 2002: 24:850-8.
5. Nagler RM, Barak M, Ben-Aryeh H, Peled M, Filatov M, Laufer D. Early diagnostic and treatment monitoring role of Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer 1999;35:15-25.
6. Kuo WR, Lee KW, Ho KY, Tsai SM, Chiang FY, Juan KH. Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumor markers in squamous cell carcinoma of the head and neck. Kaohsiung J Med Sci 1999;15:152-8.
7. Lawrence HP. Salivary markers of systemic diseases: Noninvasive diagnosis of disease and monitoring of general health. J Can Dent Assoc 2002;68:140-4.
8. Brailo V, Vučićević-Boras V, Cekić- Arambašin A, Alajbeg IŽ, Milenović A, Lukač J. The significance of salivary interleukin 6 and tumor necrosis factor alpha in patients with oral leukoplakia. Oral Oncol. 2006;42:370-3.
9. Rhodus NL, Cheng B, Myers S, Bowles W, Ho W, Ondrey F. A comparison of the pro-inflammatory, NF-kB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol 2005;114:278-83.
10. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
11. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59 (Suppl 1):i21-7.
12. Sun A, Chia JS, Chang YF, Chiang CP. Serum interleukin-6 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus. J Oral Pathol Med 2002;31:196-203.
13. Smith CW, Chen Z, Dong G, Loukinova E, Pegram MY, Nicholas-Figueroa L, et al. The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1α, IL-6, GM-CSF, and KC. Clin. Exp. Metastasis 1998;16:655-64.
14. Khandavilli SD, Ceallaigh Pó, Lloyd CJ, Whitaker R. Serum. C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol 2009:45:912-4.
15. Jablonska E, Piotrowski L, Grabowska Z. Serum levels of IL-1-β, IL-6, TNF-α, TNF-R1 and CRP in patients with oral cavity cancer. Pathol Oncol Res 1997;3:126-9.
16. Nakano Y, Kobayashi W, Sugai S, Kimura H, Yagihashi S. Expression of tumor necrosis factor-α and interleukin 6 in oral squamous cell carcinoma. Jpn J Cancer Res 1999;90:858-66.
17. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2005;29:42-5.
18. Katakura A, Kamiyama I, Takagi R, Yamada M, Shouno T, Takano N, et al. [Comparison of cytokine in saliva from oral cancer patients and normal person]. Jpn J Head Neck Cancer 2006:32:45-50. Japanese.
19. Barnes L, Eveson J, Reichart p, Sidransky D. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Head and Neck. International Agency for Research on Cancer. Lyon; IARC Press: 2005.
20. Yamamoto E, Kohama G, Sunakawa H, Iwai M, Hiratsuka H. Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer 1983;51:2175-80.
21. World Health Organization. Oral health surveys. Basic methods. Geneva: World Health Organization; 1997.
22. Gröschl M, Rauh M. Influence of commercial collection devices for saliva on the reliability of salivary steroids analysis. Steroids 2006;71:1097-100.
23. Henderson L, Muir M., Mills PR, Spence E, Fox R, McCruden EA, Bagg J. Oral health of patients with hepatic C virus infection: a pilot study. Oral Dis 2001;7:271-5.
24. Menon R, McIhtyre JO, Matrisian LM, Fortunato SJ. Salivary proteinase activity: a potential biomarker for preterm premature rupture of the membrane. Am J Obstet Gynecol 2006; 194:1609.
25. Shirasaka T, Shimamcto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-9.
26. Shikano M, Sobajima H, Yoshikawa H, Toba T, Kushimoto H, Katsumata H, et al. Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 2000;85:81-5.
27. Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA, et al. Interleukin. 6 supports the maintenance of p53 tumor suppressor gene promoter hypermethylation. Cancer Res 2005;65:4673-82.
28. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14:433-9.
29. Veltri RW, Rodman SM, Maxim PE, Baseler MW, Sprinkle PM. Immune complexes, serum protein, cell-mediated immunity, and immune regulation in patients with squamous cell carcinoma of the head and neck. Cancer 1986;57:2295-308.
30. Wolf G, Hudson JL, Peterson KA, Miller HL, McClatchey KD. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg 1986;95:142-52.
31. Karczewska A, Kawrocki S, Brȩborowicz D, Filas V, Mackiewicz A. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 1.30 correlates with good prognoses for patients with breast carcinoma. Cancer 2000:88:2061-71.
32. Rhodus NL, Cheng B, Bowles W, Myers S, Miller L, Ondrey F. Proinflammatory cytokine levels in saliva before and agter treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis 2006:12:112-6.
33. Vučićević-Boras V, Brailo V, Lukač J, Kordič D, Picek P, Blažič-Potočki Z. Salivary interleukin-6 and tumor necrosis factor alpha in patients with drag-induced xerostomia. Oral Dis 2006;12:509-11.
34. Chen F, Castranova X, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 2001;159:387-97.
35. H1 cytokines in oral lichen planus. J Oral Pathol Med 2003;32:77-83.